Vigabatrin 500 MG Powder for Oral Solution — RxCUI 250820
RxNorm drug concept · Semantic clinical drug
RxCUI 250820
Semantic clinical drug · SCD
● Current RxNorm concept 13 FDA products
13 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI250820
Official nameVigabatrin 500 MG Powder for Oral Solution
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped13
Package NDCs mapped13
Reported Medicaid activity (SDUD)15,713 prescriptions · 36 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Vigabatrin: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Vigabatrin is specifically for seizures that haven't responded well to other treatments. It's not a first choice — it's reserved for situations where other options haven't worked,...
- Why is my doctor prescribing this instead of a more common seizure medication?
- Yes, this is a real and serious risk that's important to understand. Vigabatrin can permanently narrow your field of vision — sometimes described as tunnel vision — and in some peo...
- What's this I heard about vision loss? Should I be worried?
🕸️ Concept Web — How Vigabatrin 500 MG Powder for Oral Solution Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Vigabatrin 500 MG Powder for Oral Solution
RxCUI 250820 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Vigabatrin
14851IN
-
Vigabatrin
-
Brand names 3
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Sabril
152332BN -
Vigadrone
2047863BN -
Vigpoder
2668477BN
-
Sabril
-
Dose forms 15
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Vigabatrin Powder for Oral Solution
1946399SCDF -
Vigabatrin Oral Powder Product
1946398SCDG -
Vigabatrin Oral Product
1160520SCDG -
Vigabatrin Powder for Oral Solution [Sabril]
1946401SBDF -
Vigabatrin Powder for Oral Solution [Vigadrone]
2047865SBDF -
Vigabatrin Powder for Oral Solution [Vigpoder]
2668481SBDF -
Sabril Oral Powder Product
1946402SBDG -
Sabril Oral Product
1184194SBDG - +7 more in this family
-
Vigabatrin Powder for Oral Solution
-
Clinical & branded drugs 7
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Vigabatrin 500 MG
333433SCDC -
Vigabatrin 500 MG Powder for Oral Solution [Sabril]
860898SBD -
Vigabatrin 500 MG Powder for Oral Solution [Vigadrone]
2047868SBD -
Vigabatrin 500 MG Powder for Oral Solution [Vigpoder]
2668482SBD -
Vigabatrin 500 MG [Sabril]
860893SBDC -
Vigabatrin 500 MG [Vigadrone]
2047864SBDC -
Vigabatrin 500 MG [Vigpoder]
2668478SBDC
-
Vigabatrin 500 MG
Showing up to 8 concepts per family — 19 of 26 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Vigabatrin 500 MG
SCDC · 333433 -
Vigabatrin Powder for Oral Solution
SCDF · 1946399 -
Vigabatrin Oral Powder Product
SCDG · 1946398 -
Vigabatrin Oral Product
SCDG · 1160520
Brand-Name Concepts
-
Vigabatrin 500 MG Powder for Oral Solution [Sabril]
SBD · 860898 -
Vigabatrin 500 MG Powder for Oral Solution [Vigadrone]
SBD · 2047868 -
Vigabatrin 500 MG Powder for Oral Solution [Vigpoder]
SBD · 2668482 -
Vigabatrin 500 MG [Sabril]
SBDC · 860893 -
Vigabatrin 500 MG [Vigadrone]
SBDC · 2047864 -
Vigabatrin 500 MG [Vigpoder]
SBDC · 2668478 -
Vigabatrin Powder for Oral Solution [Sabril]
SBDF · 1946401 -
Vigabatrin Powder for Oral Solution [Vigadrone]
SBDF · 2047865 -
Vigabatrin Powder for Oral Solution [Vigpoder]
SBDF · 2668481 -
Sabril Oral Powder Product
SBDG · 1946402
📦 FDA Products & Package NDCs
13 products · 13 package NDCs
13 package NDCs map to RxCUI 250820 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00245-0556-50 | 50 PACKET in 1 CARTON (0245-0556-50) / 10 mL in 1 PACKET (0... | VIGADRONE | Upsher-Smith Laboratories, LLC | 2018-06-21 |
| 31722-0009-50 | 50 PACKET in 1 CARTON (31722-009-50) / 10 mL in 1 PACKET | vigabatrin for oral solution | Camber Pharmaceuticals, Inc. | 2021-01-26 |
| 43598-0697-50 | 50 PACKET in 1 CARTON (43598-697-50) / 10 mL in 1 PACKET (4... | Vigabatrin | Dr. Reddys Laboratories Inc., | 2018-11-21 |
| 49884-0358-03 | 50 PACKET in 1 CARTON (49884-358-03) / 10 mL in 1 PACKET (4... | VIGABATRIN | Par Health USA, LLC | 2017-04-27 |
| 59651-0366-50 | 50 PACKET in 1 CARTON (59651-366-50) / 1 POWDER, FOR SOLUTI... | Vigabatrin | Aurobindo Pharma Limited | 2021-09-29 |
| 60219-1425-05 | 50 FOR SOLUTION in 1 CARTON (60219-1425-5) | Vigabatrin | Amneal Pharmaceuticals NY LLC | 2023-12-07 |
| 67386-0211-65 | 50 PACKET in 1 CARTON (67386-211-65) / 10 mL in 1 PACKET | SABRIL | Lundbeck Pharmaceuticals LLC | 2009-08-21 |
| 67877-0674-63 | 50 PACKET in 1 CARTON (67877-674-63) / 10 mL in 1 PACKET | VIGABATRIN | Ascend Laboratories, LLC | 2020-12-03 |
| 69097-0964-53 | 50 PACKET in 1 CARTON (69097-964-53) / 10 mL in 1 PACKET | VIGABATRIN | Cipla USA, Inc. | 2019-12-04 |
| 69238-1425-05 | 50 FOR SOLUTION in 1 CARTON (69238-1425-5) | Vigabatrin | Amneal Pharmaceuticals NY LLC | 2018-03-19 |
| 70710-1494-08 | 50 PACKET in 1 CARTON (70710-1494-8) / 10 mL in 1 PACKET (7... | vigabatrin | Zydus Pharmaceuticals (USA) Inc. | 2025-03-24 |
| 70771-1742-08 | 50 PACKET in 1 CARTON (70771-1742-8) / 10 mL in 1 PACKET (7... | vigabatrin | Zydus Lifesciences Limited | 2025-03-24 |
| 72205-0093-50 | 50 PACKET in 1 CARTON (72205-093-50) / 10 mL in 1 PACKET (7... | Vigabatrin | Novadoz Pharmaceuticals LLC | 2022-09-08 |
Observed labelers:
Amneal Pharmaceuticals NY LLC (2) ·
Ascend Laboratories, LLC (1) ·
Aurobindo Pharma Limited (1) ·
Camber Pharmaceuticals, Inc. (1) ·
Cipla USA, Inc. (1) ·
Dr. Reddys Laboratories Inc., (1)
· +6 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.